Antibody Drug Conjugates (ADCs) Market Report

Global and Region Antibody Drug Conjugates (ADCs) Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：163
  • REPORT CODE：GMM937566
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.  By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.  ADCs are part of a specialized subset of highly potent APIs.  This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.

    The report details the trend, potential and market size of Antibody Drug Conjugates (ADCs) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Antibody Drug Conjugates (ADCs)market, defines the market attractiveness level of Antibody Drug Conjugates (ADCs) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Antibody Drug Conjugates (ADCs) industry, describes the types of Antibody Drug Conjugates (ADCs) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Antibody Drug Conjugates (ADCs) market and the development prospects and opportunities of Antibody Drug Conjugates (ADCs) industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Antibody Drug Conjugates (ADCs) market in Chapter 13.

    By Player:

    • Roche

    • Astellas Pharma

    • Pfizer

    • ADC Therapeutics

    • AbbVie

    • Genmab

    • Seattle Genetics

    • Bayer

    • Takeda Pharmaceuticals

    • AbGenomics

    • Kairos Therapeutics

    • Novartis

    By Type:

    • Genmab Technology

    • ImmunoGen Technology

    • Immunomedics Technology

    By End-User:

    • Hospital

    • Clinics

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Antibody Drug Conjugates (ADCs) Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Antibody Drug Conjugates (ADCs) Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Antibody Drug Conjugates (ADCs) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Antibody Drug Conjugates (ADCs) Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Antibody Drug Conjugates (ADCs) Market Analysis and Outlook to 2022

    • 7.1 Global Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    • 7.2 United States Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    • 7.3 Europe Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    • 7.4 China Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    • 7.5 Japan Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    • 7.6 India Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    • 7.7 South Korea Antibody Drug Conjugates (ADCs) Consumption (2017-2022)

    8 Region and Country-wise Antibody Drug Conjugates (ADCs) Market Analysis and Outlook to 2028

    • 8.1 Global Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    • 8.2 United States Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    • 8.3 Europe Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    • 8.4 China Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    • 8.5 Japan Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    • 8.6 India Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    • 8.7 South Korea Antibody Drug Conjugates (ADCs) Consumption Forecast (2022-2028)

    9 Global Antibody Drug Conjugates (ADCs) Market Outlook by Types and Applications to 2022

    • 9.1 Global Antibody Drug Conjugates (ADCs) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Genmab Technology Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global ImmunoGen Technology Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Immunomedics Technology Consumption and Growth Rate (2017-2022)

    • 9.2 Global Antibody Drug Conjugates (ADCs) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Antibody Drug Conjugates (ADCs) Market Outlook by Types and Applications to 2028

    • 10.1 Global Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Genmab Technology Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global ImmunoGen Technology Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Immunomedics Technology Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Antibody Drug Conjugates (ADCs) Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Antibody Drug Conjugates (ADCs) Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Antibody Drug Conjugates (ADCs) Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Antibody Drug Conjugates (ADCs) Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Antibody Drug Conjugates (ADCs) Market Competitive Analysis

    • 14.1 Roche

      • 14.1.1 Roche Company Details

      • 14.1.2 Roche Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Roche Antibody Drug Conjugates (ADCs) Product and Service

    • 14.2 Astellas Pharma

      • 14.2.1 Astellas Pharma Company Details

      • 14.2.2 Astellas Pharma Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Service

    • 14.3 Pfizer

      • 14.3.1 Pfizer Company Details

      • 14.3.2 Pfizer Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Pfizer Antibody Drug Conjugates (ADCs) Product and Service

    • 14.4 ADC Therapeutics

      • 14.4.1 ADC Therapeutics Company Details

      • 14.4.2 ADC Therapeutics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Service

    • 14.5 AbbVie

      • 14.5.1 AbbVie Company Details

      • 14.5.2 AbbVie Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 AbbVie Antibody Drug Conjugates (ADCs) Product and Service

    • 14.6 Genmab

      • 14.6.1 Genmab Company Details

      • 14.6.2 Genmab Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Genmab Antibody Drug Conjugates (ADCs) Product and Service

    • 14.7 Seattle Genetics

      • 14.7.1 Seattle Genetics Company Details

      • 14.7.2 Seattle Genetics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Service

    • 14.8 Bayer

      • 14.8.1 Bayer Company Details

      • 14.8.2 Bayer Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Bayer Antibody Drug Conjugates (ADCs) Product and Service

    • 14.9 Takeda Pharmaceuticals

      • 14.9.1 Takeda Pharmaceuticals Company Details

      • 14.9.2 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Service

    • 14.10 AbGenomics

      • 14.10.1 AbGenomics Company Details

      • 14.10.2 AbGenomics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 AbGenomics Antibody Drug Conjugates (ADCs) Product and Service

    • 14.11 Kairos Therapeutics

      • 14.11.1 Kairos Therapeutics Company Details

      • 14.11.2 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Service

    • 14.12 Novartis

      • 14.12.1 Novartis Company Details

      • 14.12.2 Novartis Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Novartis Antibody Drug Conjugates (ADCs) Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Antibody Drug Conjugates (ADCs)

    • Figure Antibody Drug Conjugates (ADCs) Picture

    • Table Global Antibody Drug Conjugates (ADCs) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Antibody Drug Conjugates (ADCs) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Antibody Drug Conjugates (ADCs) Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Antibody Drug Conjugates (ADCs) Consumption by Country (2017-2022)

    • Figure United States Antibody Drug Conjugates (ADCs) Consumption and Growth Rate (2017-2022)

    • Table Europe Antibody Drug Conjugates (ADCs) Consumption and Growth Rate (2017-2022)

    • Figure China Antibody Drug Conjugates (ADCs) Consumption and Growth Rate (2017-2022)

    • Figure Japan Antibody Drug Conjugates (ADCs) Consumption and Growth Rate (2017-2022)

    • Figure India Antibody Drug Conjugates (ADCs) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Antibody Drug Conjugates (ADCs) Consumption and Growth Rate (2017-2022)

    • Figure Global Antibody Drug Conjugates (ADCs) Consumption Forecast by Country (2022-2028)

    • Figure United States Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Antibody Drug Conjugates (ADCs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Genmab Technology Consumption and Growth Rate (2017-2022)

    • Figure Global ImmunoGen Technology Consumption and Growth Rate (2017-2022)

    • Figure Global Immunomedics Technology Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Genmab Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ImmunoGen Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunomedics Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Antibody Drug Conjugates (ADCs) Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Antibody Drug Conjugates (ADCs) Export by Region (Top 5 Countries) (2017-2028)

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Antibody Drug Conjugates (ADCs) Product and Service

    • Table Astellas Pharma (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Antibody Drug Conjugates (ADCs) Product and Service

    • Table ADC Therapeutics (Foundation Year, Company Profile and etc.)

    • Table ADC Therapeutics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Service

    • Table AbbVie (Foundation Year, Company Profile and etc.)

    • Table AbbVie Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Antibody Drug Conjugates (ADCs) Product and Service

    • Table Genmab (Foundation Year, Company Profile and etc.)

    • Table Genmab Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genmab Antibody Drug Conjugates (ADCs) Product and Service

    • Table Seattle Genetics (Foundation Year, Company Profile and etc.)

    • Table Seattle Genetics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Antibody Drug Conjugates (ADCs) Product and Service

    • Table Takeda Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Service

    • Table AbGenomics (Foundation Year, Company Profile and etc.)

    • Table AbGenomics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbGenomics Antibody Drug Conjugates (ADCs) Product and Service

    • Table Kairos Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Kairos Therapeutics Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Antibody Drug Conjugates (ADCs) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Antibody Drug Conjugates (ADCs) Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US